Actavis Recalls Subpotent Vancomycin Hydrochloride Capsules Nationwide
Actavis Inc. is voluntarily recalling 51,472 cartons of Vancomycin Hydrochloride Capsules, USP, 125 mg, because the drug is subpotent.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard is a subpotent drug, which poses a risk of treatment failure without reported injuries, fitting the 'High' severity criteria for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Actavis Inc. is voluntarily recalling 51,472 cartons of Vancomycin Hydrochloride Capsules, USP, 125 mg, 2 x 10 count blister pack. The product is manufactured for Watson Pharma Inc. by Patheon Pharmaceuticals Inc. The recall was initiated on February 12, 2015, and the FDA classified it as Class II.
The reason for the recall is that the drug is subpotent, meaning it does not contain the full amount of the active ingredient required by the USP. The affected lots were distributed nationwide. The specific lot numbers and expiration dates are: 310935 (Exp 3/31/2015), 3109552 (Exp 3/31/2015), 3110204 (Exp 3/31/2015), 3112972 (Exp 7/31/2015), 3114073 (Exp 8/31/2015), 3115756 (Exp 10/31/2015), 3115888 (Exp 10/31/2015), and 3118059 (Exp 11/30/2015).
Patients who have received these specific lots of Vancomycin Hydrochloride Capsules should contact their healthcare provider for guidance. The recall was terminated on December 4, 2015.
The recalled product
- Product
- Vancomycin Hydrochloride Capsules, USP, 125 mg, 2 x 10 count blister pack, Rx Only, Manufactured for Watson Pharma Inc., Parsippany, NJ 07054, by Patheon Pharmaceuticals Inc., Cincinnati, OH. NDC 0591-3560-15
- Manufacturer
- Actavis Inc
- Category
- Drug — Antibiotic
- Hazard
- Affected units
- 51,472
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- Lot #: 310935 Exp 3/31/2015
- Lot #: 3109552 Exp 3/31/2015
- Lot #: 3110204
- Exp 3/31/2015
- Lot #: 3112972
- Exp 7/31/2015
- Lot #: 3114073
- Exp 8/31/2015
- Lot #: 3115756
- Exp 10/31/2015
- Lot #: 3115888
- Lot #: 3118059
- Exp 11/30/2015.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Actavis Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Actavis Inc
See all →- ModerateActavis Recalls Levofloxacin Ophthalmic Solution Due to Impurity Failure
FDA (Drugs) · 2017-03-15
- ModerateActavis Recalls Glipizide Extended-Release Tablets Due to Dissolution Failure
FDA (Drugs) · 2017-02-22
- LowActavis Recalls Albuterol Sulfate Inhalation Solution Due to Impurities
FDA (Drugs) · 2017-02-01
- LowActavis Recalls Hydrocortisone and Acetic Acid Otic Solution Due to Impurities
FDA (Drugs) · 2016-08-31
- LowActavis Recalls Acetasol HC Otic Solution Due to Impurity Failure
FDA (Drugs) · 2016-08-31
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02